Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNBX PharmaceuticalsCNBX +33.33% EV-to-FCF is -9.54 as of Aug. 27, 2026. The stock has 3 warning signs investors should review. Among 321 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 311526.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CNBX Pharmaceuticals's Enterprise Value is $1.48 Mil.
CNBX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in May. 2026 was $-0.16 Mil. Therefore, CNBX Pharmaceuticals's EV-to-FCF for today is -9.54.
The historical rank and industry rank for CNBX Pharmaceuticals's EV-to-FCF or its related term are showing as below:
CNBX'
s EV-to-FCF Range Over the Past 10 Years
Min: -1875.24 Med: -8.38 Max: -1.12
Current: -9.54
During the past 13 years, the highest EV-to-FCF of CNBX Pharmaceuticals was -1.12. The lowest was -1875.24. And the median was -8.38.
CNBX's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 17.48
vs CNBX: -9.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CNBX Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
CNBX Pharmaceuticals's share price for today is $0.0002.
CNBX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CNBX Pharmaceuticals EV-to-FCF Related Terms
CNBX Pharmaceuticals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CNBX Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CNBX Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNBX Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CNBX Pharmaceuticals's EV-to-FCF falls into.
CNBX Pharmaceuticals's current Enterprise Value is $1.48 Mil.
CNBX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX Pharmaceuticals (CNBX) has a EV-to-FCF of -9.54 as of Aug. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 321 companies in the Biotechnology industry.
Is CNBX Pharmaceuticals' EV-to-FCF too high?
CNBX Pharmaceuticals' current EV-to-FCF is -9.54. Based on the distribution chart, CNBX Pharmaceuticals ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' EV-to-FCF compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 321 companies for EV-to-FCF. This places CNBX Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 17.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.48, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CNBX Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CNBX Pharmaceuticals's current EV-to-FCF is -9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current EV-to-FCF of -9.54. The current EV-to-FCF is -9.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current EV-to-FCF is -9.54 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNBX has been successfully added to your 
